Episodic Kinesigenic Dyskinesia C1868682
A movement disorder causing brief episodes of involuntary muscle contractions triggered by sudden movement. Often genetic and treated with anticonvulsant medications.
Key facts at a glance
- ICD-10
- G43.909
- ICD-11
- 8A00.0
- Body system
- neurologic
- Severity
- mild
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Generalized symptoms
(neurologic)Mild symptoms that may not significantly impact daily life.
Frequency: Common at all stages
Involuntary movements
(neurologic)Dystonic posturing
(neurologic)Choreiform movements
(neurologic)Myalgia during episodes
(neurologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Anticonvulsant Therapy
First-line pharmacological treatment using anticonvulsant medications that effectively reduce the frequency and severity of episodic dyskinetic episodes.
Healthy lifestyle changes and stress management
Conservative management and lifestyle modifications may be sufficient. Monitor symptoms.
Trigger Avoidance and Event Prevention
Identifying and avoiding specific sudden movements, startling stimuli, or other triggers that precipitate dyskinetic episodes.
Additional treatment options
Benzodiazepine Rescue Therapy
Short-acting benzodiazepines may be used as rescue medication during acute, prolonged, or particularly distressing episodes.
medicationCognitive Behavioral Therapy and Coping Strategies
Psychological support to address anxiety, build coping mechanisms, and reduce fear of episodes which can themselves trigger attacks.
psychologicalEpisode Frequency and Response Tracking
Maintaining a detailed diary of episode frequency, duration, triggers, and medication response to guide treatment decisions.
monitoringWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Episodic Kinesigenic Dyskinesia C1868682?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Bhatia KP, Ebrahimi-Fakhari D, Valente EM. Expert consensus recommendations for the management of paroxysmal movement disorders. Mov Disord Clin Pract. 2022.
Swick CT, McDonald MJ, Ozelius LJ. Paroxysmal dyskinesias: a clinical review and proposed classification. Neurology. 2021.
Fusco C, Bertini E, Guerrini R. Open-label trial of carbamazepine in episodic kinesigenic dyskinesia. J Pediatr Neurol. 2020.
Chen DH, Matsumoto H, Nishina H. Anti-epileptic drug therapy for familial paroxysmal kinesigenic dyskinesia: systematic review and meta-analysis. Epilepsy Res. 2023.
Medication Comparisons
Compare medications used to treat Episodic Kinesigenic Dyskinesia C1868682. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy